



Guru Sonpavde

Contact

Guru Sonpavde

Publications (5)

Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. *Oncotarget* 2018; 9:19861-19873.

Sonpavde G, Pond G, Templeton A, Fandi A, Tombal B, Rosenthal M, Armstrong A, Petrylak D. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. *Eur Urol* 2015

Rocha P, Morgan C, Templeton A, Pond G, Naik G, Sonpavde G. Prognostic impact of C-reactive protein in metastatic prostate cancer: a systematic review and meta-analysis. *Oncol Res Treat* 2014; 37:772-6.

Templeton A, Tannock I, Tran B, Knox J, Sonpavde G, Leibowitz-Amit R, Ocana A, Aneja P, Vera-Badillo F, Seruga B, McNamara M, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; 106:dju124.

Sonpavde G, Smith M, Lechuga M, Chow-Maneval E, Chen I, Paolini J, Wang S, Templeton A, Vardy J, Clarke S, Armstrong A, Pond G, Michaelson M. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer* 2014; 12:317-24.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch